目的：通过观察恶性间皮瘤的肿瘤相关成纤维细胞(tumor-associated fibroblasts，TAF)的免疫表型特点，探讨其在诊断治疗中的意义。方法：收集恶性间皮瘤10例，食管癌、乳腺癌、结肠癌标本各10例，观察这些肿瘤TAF的CK，CK19，Calretinin，HBME-1，Vimentin，Sny，S-100等表达情况。结果：10例恶性间皮瘤、食管鳞状细胞癌、乳腺浸润性导管癌、结肠腺癌的TAF都阳性表达Vimentin，均灶状表达Syn，S-100。10例恶性间皮瘤的TAF阳性表达CK，CK19，Calretinin，弱阳性表达HBME-1；10例食管鳞状细胞癌、乳腺浸润性导管癌、结肠腺癌的TAFs均局灶弱阳性表达CK，Calretinin，不表达HMBE-1及CK19；恶性间皮瘤组的TAF表达Calretinin，CK19，CK，HBME-1的积分光密度值(integrated optical density，IOD)显高于其余3组(P<0.05)。结论：恶性间皮瘤的TAF与一般常见的上皮性肿瘤的TAF免疫表型既有共性又有不同，深入了解其免疫表型及分子生物学特性对研究恶性间皮瘤的诊断及治疗有重大意义。
Characteristics of tumor-associated fibroblasts of in malignant mesothelioma
Objective: To investigate the immune phenotype characteristics of tumor-associated fibroblasts (TAF) of malignant mesothelioma in the diagnosis and treatment by observing its immune phenotype. Methods: We respectively collected 10 cases of malignant mesothelioma, esophageal cancer, breast cancer, and colon cancer specimens, the expression of CK, CK19, Calretinin, HBME-1, Vimentin, Sny, S-100 of the TAF was observed in these tumors. Results: The TAF in 10 cases of malignant mesothelioma, esophageal squamous cell carcinoma, breast invasive ductal carcinoma, and colon adenocarcinoma were positive for Vimentin, and positive for Syn, S-100 in partial region. The TAF in 10 cases of malignant mesothelioma were positive for CK, CK19, Calretinin, and weak positive for HBME-1; 10 cases of esophageal squamous cell carcinoma, breast invasive ductal carcinoma, and colon adenocarcinoma were weak positive for CK and Calretinin in partial region, and negative for CK19 and HBME-1. The integrated optical density (IOD) value of TAF expressing Calretinin, CK19, CK and HBME-1 in malignant mesothelioma group were significantly higher than those in the other three groups (P<0.05). Conclusion: The TAF of malignant mesothelioma are both common and different from the TAF in common tumor. It is of great significance to study the diagnosis and treatment of malignant mesothelioma by studying the immune phenotype and molecular biological characteristics of the TAF.